Special Report: Reimagining QbD


Pharmaceutical Quality by Design has entered a new era-one of fading skepticism and accelerated uptake. Now that the industry has bought in, the challenge is to rethink the possibilities of what benefits QbD can provide.

In this complimentary 18-page report, leading industry and regulatory experts explore what QbD will look like in its adolescence, and how manufacturers can "reimagine" Quality by Design as a fundamental strategy involving risk, life-cycle cost, competitiveness . . . and survival. The document-which also includes links to key web resources illustrating current FDA thinking and industry practices regarding QbD-is essential for anyone wanting to know where QbD stands today, and where it's headed. Read Now.